LAUSR

One of the most commonly experienced toxicities to treatment during cancer management is cancer-related fatigue (CRF) (1). The National Comprehensive Cancer Network defines CRF as “ a distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning .” (2). This symptom represents a massive detriment to quality of life, as 50–90% of cancer patients will experience this phenomenon during their treatment (3). Furthermore, up to 30% of cancer patients will continue to experience fatigue during follow-up visits after treatment completion (4). Severity of fatigue will vary with the site of malignancy, extent of disease, and treatment modality.